Using induced pluripotent stem cells for modeling Parkinson’s disease

Minjing Ke, Cheong-Meng Chong, Huanxing Su

ORCID number: Min-Jing Ke (0000-0003-4728-6918); Cheong-Meng Chong (0000-0002-2462-4729); Huan-Xing Su (0000-0003-3254-825X).

Author contributions: Minjing Ke and Cheong-Meng Chong contributed equally to this manuscript.

Supported by: the Macao Science and Technology Development Fund, No. 039/2017/AFJ and 0020/2018/A.

Conflict-of-interest statement: The authors have declared no conflicts of interest.

Open-Access: This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Invited manuscript

Received: February 25, 2019
Peer-review started: February 27, 2019
First decision: April 11, 2019
Revised: July 26, 2019
Accepted: August 20, 2019
Article in press: August 20, 2019

Abstract

Parkinson’s disease (PD) is an age-related neurodegenerative disease caused by the progressive loss of dopaminergic (DA) neurons in the substantia nigra. As DA neurons degenerate, PD patients gradually lose their ability of movement. To date no effective therapies are available for the treatment of PD and its pathogenesis remains unknown. Experimental models that appropriately mimic the development of PD are certainly needed for gaining mechanistic insights into PD pathogenesis and identifying new therapeutic targets. Human induced pluripotent stem cells (iPSCs) could provide a promising model for fundamental research and drug screening. In this review, we summarize various iPSCs-based PD models either derived from PD patients through reprogramming technology or established by gene-editing technology, and the promising application of iPSC-based PD models for mechanistic studies and drug testing.

Key words: Parkinson’s disease; Dopaminergic neurons; Induced pluripotent stem cells; Somatic cell reprogramming; Aging

©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Human induced pluripotent stem cell (iPSC)-derived dopaminergic neurons hold great promise for studying disease mechanisms underlying Parkinson’s disease (PD) and testing drug effects. A number of reviews have previously summarized the potential use of patient iPSCs for modeling PD. However, few of them comprehensively discuss the establishment of gene-editing-based iPSCs for PD and their application in research. Our objective is to consolidate the current literature on various iPSC-based PD models either derived from PD patients through reprogramming technology or established by gene-editing technology, and provide new insights into the application of iPSC PD models.
INTRODUCTION

Parkinson’s disease (PD) is a progressive neurodegenerative disease caused by the death of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc) and a decrease in dopamine level, which lead to hypokinetic motor symptoms such as shaking, rigidity, slowness of movement, and difficulty in walking[1-3]. Although the standard treatments of PD that focus on boosting dopamine or dopamine receptor signaling can reduce symptoms at an early stage of the disease, none is effective at slowing or preventing progression of PD[4].

The onset of PD typically occurs at age > 60 years and its incidence is a global health concern with the increase in the aged population[5-8]. Aging is considered to be the most important risk factor for PD[9], but multiple factors are also widely recognized to play critical roles in its development[10]. PD is generally classified into two forms: sporadic and familial PD. Sporadic PD is usually late onset and accounts for the majority of PD cases[10]. Some genetic backgrounds have been reported to increase the incidence of sporadic PD such as cytochrome P450 2D6 and glutathione S-transferase pi 1. However, these are not defined as genetic diseases because they have not been demonstrated to be associated with the development of PD[11-13]. In addition, long-term exposure to industrial chemicals and pollutants such as pesticides[14], metals[15] and solvents[16] is considered to contribute to development of sporadic PD. Familial PD is caused by gene mutations, which accounts for about 10% of PD cases[17], and shares some clinical features with sporadic PD. Currently, 16 familial PD-related genes have been identified. Their classification depends on chromosomal locus, which is named PARK and numbered in chronological order of their identification[18-22]. Among these mutations, PARK1/4, PARK3, PARK5, PARK8 and PARK11 are identified as autosomal dominant mutations. Except for PARK1/4, the other autosomal dominant mutations are late-onset PD. Autosomal recessive mutations in PARK2, PARK6, PARK7, PARK9, PARK14 and PARK15 are reported in early-onset PD. Other mutations in vacuolar protein sorting 35 and eukaryotic translation initiation factor 4G1 are identified in PARK14 and PARK15, respectively. These findings hint that both familial and sporadic PD have similar etiology[23]. In addition, long-term exposure to industrial chemicals and pollutants such as pesticides[14], metals[15] and solvents[16] is considered to contribute to development of sporadic PD. Familial PD is caused by gene mutations, which accounts for about 10% of PD cases[17], and shares some clinical features with sporadic PD. Currently, 16 familial PD-related genes have been identified. Their classification depends on chromosomal locus, which is named PARK and numbered in chronological order of their identification[18-22]. Among these mutations, PARK1/4, PARK3, PARK5, PARK8 and PARK11 are identified as autosomal dominant mutations. Except for PARK1/4, the other autosomal dominant mutations are late-onset PD. Autosomal recessive mutations in PARK2, PARK6, PARK7, PARK9, PARK14 and PARK15 are reported in early-onset PD. Other mutations in vacuolar protein sorting 35 and eukaryotic translation initiation factor 4G1 are identified in PARK14 and PARK15, respectively. These findings hint that both familial and sporadic PD have similar etiology[23]. In addition, long-term exposure to industrial chemicals and pollutants such as pesticides[14], metals[15] and solvents[16] is considered to contribute to development of sporadic PD. Familial PD is caused by gene mutations, which accounts for about 10% of PD cases[17], and shares some clinical features with sporadic PD. Currently, 16 familial PD-related genes have been identified. Their classification depends on chromosomal locus, which is named PARK and numbered in chronological order of their identification[18-22]. Among these mutations, PARK1/4, PARK3, PARK5, PARK8 and PARK11 are identified as autosomal dominant mutations. Except for PARK1/4, the other autosomal dominant mutations are late-onset PD. Autosomal recessive mutations in PARK2, PARK6, PARK7, PARK9, PARK14 and PARK15 are reported in early-onset PD. Other mutations in vacuolar protein sorting 35 and eukaryotic translation initiation factor 4G1 are identified in PARK14 and PARK15, respectively. These findings hint that both familial and sporadic PD have similar etiology[23]. In addition, long-term exposure to industrial chemicals and pollutants such as pesticides[14], metals[15] and solvents[16] is considered to contribute to development of sporadic PD. Familial PD is caused by gene mutations, which accounts for about 10% of PD cases[17], and shares some clinical features with sporadic PD. Currently, 16 familial PD-related genes have been identified. Their classification depends on chromosomal locus, which is named PARK and numbered in chronological order of their identification[18-22]. Among these mutations, PARK1/4, PARK3, PARK5, PARK8 and PARK11 are identified as autosomal dominant mutations. Except for PARK1/4, the other autosomal dominant mutations are late-onset PD. Autosomal recessive mutations in PARK2, PARK6, PARK7, PARK9, PARK14 and PARK15 are reported in early-onset PD. Other mutations in vacuolar protein sorting 35 and eukaryotic translation initiation factor 4G1 are identified in PARK14 and PARK15, respectively. These findings hint that both familial and sporadic PD have similar etiology[23]. In addition, long-term exposure to industrial chemicals and pollutants such as pesticides[14], metals[15] and solvents[16] is considered to contribute to development of sporadic PD. Familial PD is caused by gene mutations, which accounts for about 10% of PD cases[17], and shares some clinical features with sporadic PD. Currently, 16 familial PD-related genes have been identified. Their classification depends on chromosomal locus, which is named PARK and numbered in chronological order of their identification[18-22]. Among these mutations, PARK1/4, PARK3, PARK5, PARK8 and PARK11 are identified as autosomal dominant mutations. Except for PARK1/4, the other autosomal dominant mutations are late-onset PD. Autosomal recessive mutations in PARK2, PARK6, PARK7, PARK9, PARK14 and PARK15 are reported in early-onset PD. Other mutations in vacuolar protein sorting 35 and eukaryotic translation initiation factor 4G1 are identified in PARK14 and PARK15, respectively. These findings hint that both familial and sporadic PD have similar etiology[23].
rotenone in rats leads to aggregation of α-synuclein, DA neurodegeneration and behavior defects. A major concern about rotenone-induced models is that, in addition to degeneration of nigral DA neurons, rotenone causes pronounced degeneration in basal ganglia and brainstem nuclei[37,38], and leads to high systemic toxicity[39].

Transgenic mice are alternative models for exploring pathogenic mechanisms of PD-linked genetic factors. Currently, duplication or triplication of the α-synuclein locus could cause PD symptoms[40], indicating that increasing expression of PD-related genes could be applied to establishment of PD models[41,42]. Some PD characteristics can be observed in transgenic mice generated by overexpressing wild-type PD genes or PD gene mutation at age ≤ 2 years[43]. However, in mammalian models, knockin or knockout mutation of PD-linked genes can only cause a moderate decrease in striatal DA levels accompanied by low locomotor activity in an age-dependent manner, without evident loss of dopaminergic neurons in SNpc[44]. Transgenic mouse models may illuminate some pathogenic processes of PD, but cannot fully replicate the phenotypes of human PD because they are insufficient to cause significant nigral degeneration within the animal lifespan[45]. The genetic mouse models may not properly represent interaction of genetic factors, aging process, and environmental insults in human PD[46]. Thus, establishing suitable models to fully represent the characteristics of PD is urgently needed.

Human induced pluripotent stem cells (iPSCs) are generated from somatic cells by reprogramming. The somatic cells reprogramming technology was pioneered by Shinya Yamanaka in 2006 and showed that introduction of four transcription factors (OCT4, SOX2, KLF4 and c-MYC) could convert somatic cells into PSCs[47]. The ability of iPSCs to differentiate into DA neurons overcomes the challenges and shortcomings associated with PD modeling. Two types of iPSC-based PD models are widely used: patient-specific and gene-modifying models. Patient-derived specific disease models have been used in discovering novel biomarkers for diagnosis or candidate drug therapy[48]. Genome editing can offset the variation of genetic background among individuals[49,50]. In this review, we summarize various iPSC-based PD models either derived from PD patients through reprogramming technology or established by gene-editing technology, and the promising application of iPSC-based PD models for mechanistic studies and drug testing (Figure 1).

**PATIENT-SPECIFIC iPSCs**

It is widely accepted that PD results from a complex interaction of environmental and genetic factors[51,52]. In the hope of copying traits of PD, DA neurons derived from PD-patient-specific iPSCs display the cellular characteristics of PD in vitro. Investigators have established iPSC banks of neurodegenerative disease over the past decade. To date, patient-specific iPSCs have been used in a variety of fields including drug discovery, basic research and cytotoxicity testing.

**iPSC models for familial PD**

It is well known that sporadic PD occupies > 90% of total PD cases, but genetic factors still play an important role in understanding PD etiology. The use of genetic PD iPSCs offers the promise of addressing the contribution of individual genetic factors and functional relevance of underlying molecular pathways in the development of PD. Currently, 16 familial PD-related genes have been identified. Among them, SNCA, LRRK2, Parkin, PINK1 and GBA mutations have mostly been studied in genetic PD iPSCs[46] (Table 1). Researchers have made efforts to illustrate the pathological features of DA neurons or other neuronal cells derived from these genetic PD iPSCs. It is generally considered that the fate of these mutated genes is often loss of function that induces aberrant accumulation of inactive proteins[53].

Accumulation of α-synuclein is a major feature of PD, which is encoded by SNCA gene. SNCA A53T mutant and triplication SNCA are familial PD SNCA mutants. In these patients, α-synuclein level in the midbrain region is three times that in somatic cells, revealing that it is easy to cause accumulation of α-synuclein in DA neurons. After Soldner et al.[54] successfully generated the first DA neurons from SNCA mutant iPSCs, a number of SNCA A53T mutant or triplication SNCA mutant iPSC lines were generated, and elevated α-synuclein levels were found in these iPSC-derived DA neurons[55,56]. Other cellular types such as forebrain cortical neurons, neural precursor cells, and GABAergic neurons were further induced from SNCA mutant iPSCs, and endoplasmic reticulum (ER) stress, oxidative stress, or maturation inability but no significant alteration of α-synuclein protein or mRNA level were detected in these iPSC-derived cells[57,58]. These studies show that SNCA gene mutations may have great influence on a variety of neuronal subtypes and not just DA neurons.
Figure 1 Potential applications of induced pluripotent stem cells for study of Parkinson's disease. Somatic cells are extracted from either normal individuals or patients and then reprogrammed to induced pluripotent stem cells (iPSCs). Gene editing technology enables one to generate knockin mutant Parkinson's disease (PD) iPSCs and isogenic control cell lines. Dopamine (DA) neurons can be successfully differentiated from iPSCs. Both patient-derived and gene-editing iPSCs could be powerful tools for modeling PD for mechanistic studies and drug discovery. Healthy or corrected iPSCs could serve as normal controls and cell sources for cell therapy. iPSCs: Induced pluripotent stem cells; DA: Dopaminergic.

N1437H, R1441C and G2019S mutations of \textit{LRRK2} are known to cause PD. Among them, G2019S is the most common familial PD mutation in \textit{LRRK2}[60]. Many studies have pointed out the crucial role of the loss-of-function of \textit{LRRK2} mutant in reducing neurite outgrowth and numbers, and process complexity[61-65]. Oxidative stress, mitophagic dysfunction, and DNA damage have been observed in \textit{LRRK2} G2019S iPSC-derived DA neurons. In addition, self-renewal and neuronal differentiation of \textit{LRRK2} G2019 mutant neural stem cells are reported to be impaired, providing evidence on the crucial role of \textit{LRRK2} in neural development[62].

Synergistic effect of \textit{PINK1} and \textit{Parkin} are important to maintain cellular homeostasis such as mitochondrial quality in DA neurons[66,67]. It is suggested that overexpression of \textit{Parkin} can largely rescue the defects in \textit{PINK1} mutants through mitochondrial translocation[66,68]. \textit{Parkin} improves the uptake of dopamine through enhancing the expression of DAT as well[69]. \textit{PINK1} or \textit{Parkin} mutant iPSC-derived DA neurons display abnormal phenotypes such as mitophagy and autophagy impairment, vulnerability to various stresses, and accumulation of peroxisome proliferator-activated receptor-γ coactivator 1α (PGC1α), which are consistent with previous studies[63,70-75]. These findings support the synergistic effect of \textit{PINK1} and \textit{Parkin}, providing an inspiration for developing therapeutic strategies for PD.

\textit{GBA1} gene mutations are reported to be associated with an increased risk of sporadic PD[76]. A number of studies on patient-specific iPSC-derived DA neurons harboring \textit{GBA1} mutations have indicated that \textit{β}-glucocerebrosidase (\textit{GBA1}) has high correlation with elevated α-synuclein levels as well as autophagic and lysosomal defects[77-79]. Furthermore, calcium homeostasis imbalance, and reduced dopamine storage and uptake are also found in \textit{GBA1} mutant DA neurons[77-79]. However, how these above-mentioned phenotypes are triggered by \textit{GBA1} mutant remains to be explored.

**iPSC models for sporadic PD**

Sporadic PD-derived iPSCs lack known PD mutations. The first case of generation of sporadic PD patient iPSCs was reported by Soldner et al[80]. They generated iPSCs from skin biopsies obtained from sporadic PD patients by application of modified lentiviruses carrying loxP sites flanking the integrated provirus for improving the efficiency of reprogramming. The advantage of this method was the use of inducible excisable lentivirus, rendering the iPSCs free of reprogramming transgenes. However, the phenotypic analysis of these iPSCs was not performed in that study. Sanchez-Danes et al[71] generated healthy and sporadic PD iPSCs via retroviral delivery of...
| Gene mutation       | Inheritance type | Differentiated cell types | In vitro phenotypes (normalized to normal control / non-isogenic control)                                                                 | Ref. |
|---------------------|------------------|--------------------------|----------------------------------------------------------------------------------------------------------------------------------------|------|
| A53T SNCA          | Familial         | DA neurons               | Not demonstrated                                                                                                                      | [52] |
| Triplication SNCA  | Familial         | DA neurons               | Elevated levels of SNCA mRNA Increased cellular and secreted α-synuclein protein                                                      | [66] |
| Triplication SNCA  | Familial         | DA neurons               | Elevated a-synuclein protein expression Increased expression of oxidative stress-related genes Increased susceptibility to oxidative stress | [95] |
| SNCA (A53T)/triplication SNCA | Familial | Forebrain cortical neurons | Nitrosative stress Accumulation of ERAD substrates ER stress                                                                             | [96] |
| Triplication SNCA  | Familial         | Neural precursor cells   | High vulnerability to stress Increased ROS production                                                                                  | [94] |
| Triplication SNCA  | Familial         | Neural precursor cells/DA neurons | Impaired neuronal differentiation and maturation pSer129-aSyn accumulation Increased susceptibility to oxidative stress                  | [94] |
| SNCA (A53T)        | Familial         | DA, GABAergic, and glutamatergic neurons | Protein aggregation (thioflavin S and pSer129-aSyn) Axonal neuropathology Altered expression of synaptic transcripts | [95] |
| LRRK2 (G2019S)     | Familial         | DA neurons               | Reduced neurite outgrowth Dysregulated autophagy system Increased cell death in response to neurotoxins Elevated asynuclein protein level Dysregulation of genes related to DA neurodegeneration | [65] |
| LRRK2 (G2019S)     | Familial         | Neural stem cells        | Increased sensitivity to stress Progressive impairment in nuclear envelope organization Defective self-renewal and neuronal differentiation | [65] |
| PINK1 (Q456X)      | Familial         | DA and nonDA neurons, and immature cells | Increased vulnerability to stress Dysfunction of mitochondria                                                                           | [65] |
| LRRK2 (G2019S)     | Familial         | DA neurons               | Increased neuronal death Degenerated dendrites Impaired Akt signaling                                                                       | [77] |
| PINK1 (Q456X or R275W) | Familial | DA neurons               | Increased apoptosis Reduced neurite numbers and complexity Increased autophagic vacuoles                                                 | [61] |
| PARK2 (V324A)      | Familial         | DA neurons               |                                                                                                                                         | [75] |
| LRRK2 (G2019S) and Sporadic | Familial and Sporadic | DA neurons               |                                                                                                                                         | [61] |
| SCNA (A53T)        | Familial         | DA neurons               | Elevated asynuclein aggregation and Lewy-body-like deposition Induced nitrosative and oxidative stress Increased vulnerability to mitochondrial toxin-induced cell death | [95] |
| SCNA (A53T)        | Familial         | DA neurons               | Decreased asynuclein tetramers Increased neurotoxicity                                                                                 | [94] |
| Genetic Variant | Pathology | DA Neuron Phenotype | References |
|-----------------|-----------|---------------------|------------|
| PARK2 (exon 2–4 deletion or exon 6, 7 deletion) | Familial | Increased oxidative stress, activated NRF2 pathway | [70] |
| PARK2 (exon 3, 5 deletion or exon 6, 7 deletion) | Familial | Decreased dopamine uptake, enhanced spontaneous dopamine release | [71] |
| PINK1 (c.1366C>T; p.Q456X or c.509T>G; p.V170G) | Familial | Impaired recruitment of Parkin to mitochondria, increased mitochondria copy number, PGC1α upregulation | [74] |
| PARK2 (exon 3, 5 deletion or exon 3 deletion) | Familial | Reduced neurite complexity, diminished microtubule stability | [73] |
| LRRK2 (G2019S) and sporadic PD | Familial/sporadic | Elevated oxidative stress, increased sensitivity to stress-induced cell death | [64] |
| GBA1 (L444P/+ or N370S/+ and sporadic type) | Familial/sporadic | Reduced storage and uptake of dopamine, elevated α-synuclein and glucosylceramide levels, disrupted network activity | [78] |
| GBA (N370S/+ and sporadic type) | Familial/sporadic | Elevated α-synuclein levels, reduced dopamine levels, disrupted network activity, disease-associated risk variant that regulates SCNA expression | [79] |
| SCNA SNP | Sporadic | Disease-associated risk variant that regulates SCNA expression | [10] |
| SCNA (A53T) | Familial | Elevated nitrosative stress, SNCAAS3T or mitochondrial toxins induce S-nitrosylated (SNO)-MEF2C in DA neurons, S-nitrosylation of MEF2C reduces PGC1α expression and impairs mitochondrial function | [54] |

ERAD: Endoplasmic-reticulum-associated degradation; MAOB: Monoamine oxidase B; NRF2: Nuclear factor erythroid 2-related factor 2; SNP: Single-nucleotide polymorphism; TH: Tyrosine hydroxylase.

OCT4, KLF4 and SOX2, and then differentiated them into DA neurons. By comparing with the healthy control group, they found that DA neurons differentiated from sporadic PD-patient-derived iPSCs after long-term culture displayed increased expression of cleaved caspase 3, shortened neurite length, and defective autophagosome clearance[81]. Fernández-Santiago et al[65] reported genome-wide DNA methylation of DA neurons derived from LRRK2-mutant and sporadic PD patients to explore the relationship between DNA methylation and alteration of gene expression and enhancer elements. They found that alterations of epigenetic signature significantly affected DNA methylation in sporadic PD patients. This study provides evidence that it is a common phenomenon that aberrant protein turnover and altered morphology and methylation patterns occur in sporadic PD-patient-derived DA neurons. Piwi-interacting RNA (piRNA) seems to have relevance to aberrant protein...
turnover and altered morphology and methylation patterns in sporadic PD-patient-derived DA neurons. piRNA is a complex of piwi protein and RNA, and is a large class of small noncoding RNA molecules expressed in animal cells that are involved in the epigenetic and post-transcriptional silencing of transposons. Schulze et al(85) have shown that the specific alteration of sin- and line-derived piRNA in DA neurons could be a new mechanism for the causation of PD(82-84).

**ipSCs-derived astrocytes in PD modeling**

Astrocytes are the major group of cells in the central nervous system, with a range of functions that provide both structural and metabolic support for neurons. Accumulating evidence suggests that astrocyte dysfunction leads to the pathogenesis of PD, especially familial PD(86-88). As summarized by Booth et al(89), mutations in DJ-1, SNCA, PLA2G6, LRRK2 and GBA lead to abnormal glutamate uptake, mitochondrial dysfunction, inflammatory response, water transport defect, and autophagy impairment. Gunhanlar et al(90) found that in a coculture system of astrocytes and neurons at a consistent ratio (60:40), neuron maturation was distinctly upregulated according to electrophysiological maturity. Accordingly, astrocytes are widely used in implementing cellular modeling approaches to the study of neurodegenerative disorders(89). Similarly, astrocytes could help DA neurons defend against the neurotoxins and attenuate the mitochondrial dysfunction, as observed by Feng et al(89).

Remarkably, the astrocytes and neuron co-culture system improved the outgrowth of neuron markers, and stabilized the mitochondrial function through downregulation of ROS and increased mitochondrial function(89). On the contrary, astrocytes were also used in inducing PD degeneration phenotypes by Santos et al(91) and Di Domenico et al(91). In Santos et al’s research, astrocytes were activated and became inflammatory, and were co-cultured with DA neurons(90), while Di Domenico et al(92) co-cultured PD-patient-derived astrocytes with normal DA neurons. Normal DA neurons were induced to display apoptosis and multiple system dysfunction after co-culture with dysfunctional astrocytes(92-93). These compelling findings emphasized that astrocytes may substantially participate in PD pathogenesis (Table 2).

### GENOME-EDITING-BASED ipSCs and ISOCENIC CONTROLS

Since Yamanaka opened the door for the generation of iPSCs(41), iPSCs differentiation into DA neurons is commonly used for studying PD pathophysiology. Appropriate healthy iPSC-derived cells with higher quality and availability are often used as controls to study the phenotypes of a patient’s iPSC-derived cells. However, differences in genetic background are of concern: healthy siblings used as controls share only about 50% of the genome of patients(91). The differences in genetic background lead to higher variations in phenotypic presentation. This critical issue should only be interpreted via comparison with isogenic control cells(84). A locus mutation or target gene correction is introduced by editing a specific site in the human genome of iPSCs, which has become a routine procedure in many studies of PD iPSCs. Many genome-editing tools, including zinc-finger nucleases (ZFNs), transcription activator-like effectors (TALENs) and CRISPR/Cas9 system are commonly used in editing iPSCs(93). Among them, CRISPR/Cas9 may be the best one in gene editing because of the prospect of flexibility in site selection and affordability, although there are still some concerns about the efficacy and off-target risk(93). The bottleneck in investigating connections between gene function and disease mechanisms is likely to be overcome by these genome-editing technologies.

Many iPSC PD cell lines have been established with genome editing (Table 3). Soldner et al(93) performed genetic correction in A53T (G209A) α-synuclein mutation in PD patient-derived iPSCs via ZFN-based gene editing. The G2019S mutation in LRRK2 is the most common cause of familial PD. Reinhardt et al(94) performed genetic correction of an LRRK2 mutation in PD-patient iPSCs via ZFN-based gene editing and Cre/LoxP systems, and linked parkinsonian neurodegeneration to extracellular signal-regulated kinase (ERK)-dependent changes in gene expression. They further demonstrated that ERK inhibitor reduces multiple PD-associated phenotypes, including lower neurite outgrowth, autophagy defects, synaptic defects, increased apoptosis, accumulation of tau and α-synuclein in LRRK2 G2019S mature DA neurons. Sanders et al reported that LRRK2 G2019S iPSC-derived DA neurons displayed greater levels of mitochondrial DNA damage, whereas this abnormal mitochondrial damage was no longer detected in corrected iPSC-derived neurons by ZFN-mediated genomic correction(95). The mutations and genomic multiplications of the SNCA gene (α-synuclein) account for up to 15% of cases of familial PD(96,97).
### Table 2  Induced pluripotent stem cell-derived astrocytes in Parkinson’s disease modeling

| Cell lines                        | Differentiated types                                      | Phenotype demonstrated                                                                 | Ref |
|-----------------------------------|-----------------------------------------------------------|----------------------------------------------------------------------------------------|-----|
| Bone marrow 2-3(BM2-3) hiPSCs     | Astrocytes/DA neurons coculture system                    | Elevated DA neuron identities, Stabilization of mitochondrial function, Downregulation of mitoROS, Increased mitochondrial length (normalized to non-co-culture DA neurons) | [88]|
| iPSCs and ESCs                    | Astrocytes/DA neurons coculture system                    | Non-activated astrocytes co-culture system improved DA neurons survival, Non-activated astrocytes co-culture system increased DA neurons neurite lengths (normalized to inflammatory-activated astrocytes coculture system) | [89]|
| LRRK2 mutant and normal iPSCs     | PD Astrocytes/normal DA neurons coculture system           | Non-cell-autonomous damage is triggered by impaired autophagy in PD astrocytes, Dysfunctional PD astrocytes accumulate and transfer α-synuclein to healthy DA neurons, CMA activator drug prevents α-synuclein accumulation and neurodegeneration (normalized to the single culture system) | [90]|

iPSCs: Induced pluripotent stem cells; ESCs: Embryonic stem cells; hiPSCs: Human induced pluripotent stem cells; PD: Parkinson’s disease; DA: Dopaminergic.

Soldner et al.\cite{52} used CRISPR/Cas9-mediated insertion and exchange of risk-associated enhancer sequences. They identified a common PD-associated risk variant in a noncoding distal enhancer element that regulates expression of SNCA. Arias-Fuenzalida et al.\cite{98} induced heterozygous missense A30P and A53T mutations in the SNCA gene in healthy iPSCs via combined use of CRISPR/Cas9 and fluorescence-activated cell sorting analysis. These edited SNCA mutant iPSC-derived neuroepithelial stem cells displayed a significant decrease in maximal respiration, proton leak, basal respiration, ATP production, and nonmitochondrial respiration for the extracellular energy flux. Qing et al.\cite{48} used CRISPR/Cas9 and piggyBac system to establish heterozygous LRRK2 G2019S mutation in healthy iPSCs. They observed that the number of tyrosine-hydroxylase-positive neurons and their neurite complexity were significantly decreased in LRRK2 G2019S DA neurons.

### CHALLENGES IN USING iPSCs TO MODEL PD

**Efficient generation of DA neurons from human iPSCs**

DA neurons modulate several brain functions such as motor control, reward behavior, and cognition\cite{99}. Recapitulation of the in vivo developmental profile of a specific cell type provides a powerful strategy for manipulating cell-fate choice during the process of human iPSC differentiation. In vitro generation of functional DA neurons is critical in pluripotent cell biology for both experimental and clinical applications. The neural stem/progenitor cell (NSPC) strategy and the floor-plate cell strategy are two useful protocols for generating DA neurons. The NSPC strategy is widely used in neuronal differentiation, in which NSPCs are isolated from rosettes\cite{100,101} or induced by defined medium with many supplements\cite{102}. The floor-plate strategy was proposed by Hynes et al.\cite{103} and is based on the fact that the floor plate is a critical signaling center during neural development located along the ventral midline of the embryo. Lorens et al.\cite{100} derived the floor-plate cells from human embryonic stem cells (hESCs) using a modified protocol by dual Smad inhibition. The floor-plate cells are predisposed to differentiate into mature ventral midbrain DA neurons with a higher efficiency than rosette-based neurons\cite{100}. The floor-plate-derived midbrain DA neurons are able to control dopamine release and selective dopamine reuptake, as well as other features such as synaptic transmission. Importantly, PD patient iPSC-derived DA neurons show cellular PD phenotypes such as increased accumulation of mitochondrial ROS and cytoplasmic α-synuclein, mitochondrial DNA damage, shortened neurites, and impaired autophagy\cite{80,104,105}.

**Disease phenotypes in modeling late-onset PD**
### Table 3  Pluripotent stem cell-based genome-editing Parkinson’s disease models

| Gene mutation | Editing system | Cell line | Phenotype demonstrated | Application | Ref. |
|---------------|----------------|-----------|------------------------|-------------|------|
| SNCA A30P     | CRISPR/CAS9    | hiPSC     | Not demonstrated       | Locus mutation | [48] |
| LRRK2 G2019S  | ZFN            | hiPSC     | Not demonstrated       | Gene correction | [95] |
| LRRK2 G2019S  | CRISPR/CAS9    | hiPSC     | Synaptic defect, fraction of TH+/S129P-αS+ neurons was significantly reduced | Locus mutation | [48] |
| SNCA E46K     | ZFN            | hESC      | Not demonstrated       | Locus mutation | [91] |
| SNCA A53T     | ZFN            | hiPSC     | Not demonstrated       | Gene correction | [91] |
| SNCA A30P/A53T| CRISPR/CAS9    | hiPSC     | Not demonstrated       | Locus mutation | [91] |
| SNCA (rs356165 A/G) | CRISPR/CAS9 | hiPSC | Basic phenotypes: autophagy defects, synaptic defects, increased apoptosis, accumulation of α and α-synuclein. Phenotypes were alleviated after genetic correction | Gene correction | [91] |
| LRRK2 G2019S  | ZFN            | hiPSC     | Not demonstrated       | Locus mutation | [91] |

hiPSC: Human induced pluripotent stem cell.

Aging is a crucial risk factor for all late-onset neurodegenerative diseases. One important challenge found in iPSC-based PD models is to appropriately reproduce the late-onset characteristics. Reprogramming somatic cells to iPSCs resets their identity back to an embryonic state. The ability of iPSCs to undergo unlimited division while maintaining genomic integrity provides a way to overcome the senescence barrier. Even if these iPSCs differentiate into mature DA neurons, it still needs a lot of time to culture for mimicking aging DA neurons, presenting a significant hurdle for modeling PD. Thus, how to induce aging in iPSC-derived DA neurons is an important issue. Justine et al.[72] compared young and aged human fibroblasts; they found a predominant difference in progerin level between adolescent and aged cells. They further demonstrated that overexpression of progerin in PD iPSC-derived DA neurons in vitro or in vivo promoted cell aging for modeling late-onset PD features such as pronounced dendrite degeneration, progressive loss of tyrosine hydroxylase expression, and enlarged mitochondria or Lewy body inclusions[72]. Thus, progerin expression could accelerate aging in iPSC-derived DA neurons for inducing PD pathogenic phenotypes, and introducing progerin expression could be a useful strategy to manifest disease phenotypes in iPSC-based late-onset PD models. However, it should be noted that neurons are fragile for undertaking the delivery of exogenous genes. The low efficiency of transfection in neurons remains a big challenge for widespread and convenient application of progerin expression to model iPSC-based late-onset neurodegenerative diseases.

Previous studies have indicated that chronic treatment with anticancer drug hydroxyurea (HU) could induce cellular senescence in human fibroblasts[109] and mouse neural stem cells[110]; via induction of genes related to DNA damage and repair, mitochondrial dysfunction, and ROS increase. In our recent study[108], we found that HU-induced disease phenotypes of sporadic PD-patient-specific iPSC-derived DA neurons. HU treatment significantly reduced neurite outgrowth, expression of p-Akt and its downstream targets (p-4EBP1 and p-ULK1), as well as increased the level of cleaved caspase 3 in iPSC-derived DA neurons from sporadic PD patients. Transcriptome analysis and Western blotting indicate that HU alters the expression of genes and proteins related to the ER stress pathway in healthy iPSC-derived DA neurons. It reveals that ER stress might contribute to HU-induced aging in iPSC-derived DA neurons from sporadic PD patients. Our study also found that the midbrain characteristics decline after iPSC-derived DA neurons are treated with HU, which is similar to the characterization of PD. Thus, increasing chemically induced ER stress could be an alternative approach to accelerating aging of iPSC-derived DA neurons from PD patients for manifestation of PD cellular phenotypes.

### POTENTIAL APPLICATION OF iPSCs IN PD
**iPSCs-based mechanistic studies for exploring clinical therapeutic strategies**

Due to the ability of human iPSCs to differentiate into human DA neurons and astrocytes, human iPSCs are a promising model for studying the pathogenesis of PD. Compared with neurotoxin-induced injuries, human iPSC-derived DA neurons from sporadic or familiar PD patients could give help us to understand the progressive changes of PD neuronal phenotypes as culture time increases[50,109]. Through this PD iPSCs model, we can verify the possible mechanisms of pathogenesis suggested in previous studies in other cell or animal models. Most importantly, studying these PD-iPSC-derived DA neurons could explain how the clinical degenerative features of human DA neurons occur[106,111]. At least the changes in some human familial PD-iPSC-derived neurons can represent the middle or final stage of PD because this iPSC-derived DA neuronal death occurs with α-synuclein accumulation, which is consistent with the observation in PD patients. Compared with familial PD, the etiology of sporadic PD is still a major challenge because of the multifactorial etiopathogenesis of sporadic PD. Since sporadic PD is complicated, the changes in neuronal phenotype cannot reflect the pathogenic alteration in the whole brain or other systems of sporadic PD patients[110,111].

**iPSCs as a powerful and convincing drug discovery tool in PD**

Current PD therapies help patients relieve motor symptoms, but do not effectively prevent, slow or halt the progression of PD, particularly in the loss of DA neurons[114]. Neurotoxin-based neurons or animal models are commonly used for anti-PD drug screening. Many drugs based on these artificial models have been developed but do not significantly prevent PD progression[115]. One reasonable explanation is that these neurotoxins that usually cause strong injuries in DA neurons cannot mimic the progressive death of human DA neurons in PD. In addition, DA neurons from animals are distinct from human DA neurons. In PD-iPSC-derived DA neurons, the typical PD features such as accumulation of α-synuclein, progressive degeneration, and death could be observed. These robust and reproducible PD phenotypes are amenable to screening potential compounds. Thus, PD-iPSC-derived DA neurons are more suitable for screening anti-PD drugs than artificial models are.

**iPSC-based research enhanced development of cell therapy**

The inspiring success in PD treatment was achieved through allograft of human fetal midbrain cell suspensions in 1980[116]. In addition, in MPTP-treated monkey brains, monkey ESC-derived neural progenitor cells differentiated into DA neurons and cells integrated well in the striatum, thereby PD-related motor symptoms improved[117]. Compared with ESCs, iPSCs have more potential in cell replacement therapies for PD because they can be generated from patients’ own cells and differentiate into DA neural progenitor cells that specifically develop into DA neurons[118]. iPSCs have the advantage of eliminating immune rejection concerns as they are obtained from the host. The generation of iPSCs from a patient’s own somatic cells would potentially allow for a plentiful source of cells for autotransplantation. In addition, using iPSCs rather than ESCs means that this treatment would be potentially available in some countries that ban the application of ESCs, including Italy, Ireland, and most African and South American countries[119,120]. For familial PD patients, the corrected iPSCs are also a reasonable source for the transplantation of normal DA neurons to reduce motor symptoms. Recently, scientists from Japan have started a clinical trial[121] (ClinicalTrials.gov NCT02452723) to treat PD with human iPSCs. All these suggest that the transplant of human iPSCs-derived DA neurons will be a promising therapeutic strategy and customized treatment is practical due to individual differences.

**CONCLUSION**

In this review, we have summarized iPSC-based PD models from patient-specific as well as genome-editing-based iPSCs. Patient-specific iPSCs that harbor the disease-associated genotype have provided extensive insights into pathogenic mechanisms of PD. However, given inherent genetic heterogeneity between individuals, it is understandable that disease phenotypes could be confounded by use of patient-specific iPSCs with different genetic backgrounds. The use of gene-targeting strategies based on ZFNs, TALENs or CRISPR/Cas9 to induce or correct a particular genetic mutation, has become indispensable in developing isogenic lines with and without a disease genotype. However, although great advances have been made in gene editing, high off-target risk and low efficacy still make it difficult and time-consuming in generating genome-editing-based iPSCs. Thus, improving the efficiency and precision
of gene editing is important for generating more isogenic PD-specific iPSCs and control cell lines. How to reliably establish iPSC-based models for late-onset PD remains to be resolved. Inducing an aged state by long-term culture, overexpression of an aging protein, or small molecules is encouraged in most iPSC-based age-related PD models. Finally, iPSCs cannot mimic motor symptoms and some nonmotor symptoms such as depression, apathy, hypomobility, and impairment of cognition. Thus, how to bridge the gap between animal and cell studies should be addressed in the future.

REFERENCES

1. Kalita JV, Lang AE. Parkinson disease in 2015: Evolving basic, pathological and clinical concepts in PD. Nat Rev Neurol 2016; 12: 65-66 [PMID: 26782338 DOI: 10.1038/nrneurol.2015.249]

2. Alota Ignacio Pereira V, Augusto Barbieri F, Moura Zagatto A, Cesar Rocha Dos Santos P, Simieli L, Augusto Barbieri R, Pivetta Carpes F, Teresa Bucken Gobbi L. Muscle Fatigue Does Not Change the Effects on Lower Limbs Strength Caused by Aging and Parkinson's Disease. Aging Dis 2018; 9: 988-998 [PMID: 30574412 DOI: 10.14336/AD.2018.0203]

3. Chong CM, Shen M, Zhou ZY, Pan P, Hoi PM, Li S, Liang W, Ai N, Zhang LQ, Li CW, Yu H, Hou T, Lee SM. Discovery of a benzofuran derivative (MBPTA) as a novel ROCK inhibitor that protects against MPP⁺-induced oxidative stress and cell death in SH-SY5Y cells. Free Radiol Biol Med 2014; 74: 283-293 [PMID: 24973649 DOI: 10.1161/feradbiomed.2014.06.014]

4. Benito-León J, Bermejo-Pareja F, Morales-González JM, Porta-Etessam J, Trincado R, Vega S, Louis ED. Neurological Disorders in Central Spain (NEDICES) Study Group. Incidence of Parkinson disease and Parkinsonism in three elderly populations of central Spain. Neurology 2004; 62: 734-741 [PMID: 15007123 DOI: 10.1212/01.wnl.0000113727.73153.68]

5. de Lau LM, Giesbergen PC, de Rijk MC, Hofman A, Koudstaal PJ, Breteler MM. Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam Study. Neurology 2004; 63: 1240-1244 [PMID: 15477545 DOI: 10.1212/00002293-0000000000001193]

6. Shetty AK, Kodali M, Upadhye R, Madhun LN. Emerging Anti-Aging Strategies - Scientific Basis and Efficacy. Aging Dis 2018; 9: 1165-1184 [PMID: 30574426 DOI: 10.14336/AD.2018.10.1026]

7. Zhao YF, Qiong-Zhang, Zhang JF, Lou ZY, Zu HB, Wang ZG, Zeng WC, Kai-Yao, Xiao BG. The Synergy of Aging and LPS Exposure in a Mouse Model of Parkinson's Disease. Aging Dis 2018; 9: 785-797 [PMID: 30271656 DOI: 10.14336/AD.2018.10.1026]

8. Defazio G, Abbruzzese G, Aniello MS, Boisse M, Crisci C, Eleopra R, Fabbrini G, Girlanda P, Liguori R, Macerollo A, Marinelli L, Martinod D, Morgante F, Santoro L, Tinazzi M, Berardelli A. Environmental risk factors and clinical phenotype in familial and sporadic multiple blepharospasm. Neurology 2011; 77: 631-637 [PMID: 21775731 DOI: 10.1212/01.wnl.0000118229.96135.8a]

9. Kalita JV, Lang AE. Parkinson's disease. Lancet 2015; 386: 896-912 [PMID: 25904081 DOI: 10.1016/S0140-6736(14)61393-3]

10. Hamza TH, Zabetian CP, Tenesa A, Laeradach A, Montimuro J, Yearout D, Kay DM, Dohney KY, Paschall J, Pugh E, Kusel VI, Collura R, Roberts J, Griffith A, Samii A, Scott WK, Nutt J, Factor SA, Payami H. Common genetic variation in familial and sporadic multiple blepharospasm. Neurology 2011; 77: 631-637 [PMID: 21775731 DOI: 10.1212/WNL.0b013e31822989f3]

11. Alonso-Nava R, Herrera-Cazares RR, Rios-Jimenez AL, Mejia-Jimenez FL, Garcia-Alberto A, Agundez JA. Genomic and Pharmacogenomic Biomarkers of Parkinson's Disease. Curr Drug Metab 2014; 15: 129-181 [PMID: 24694231 DOI: 10.2174/138920021502140327175404]

12. Singh NK, Banerjee BD, Bala K, Chhillar M, Chhillar N. Gene-gene and gene-environment interaction on the risk of Parkinson's disease. Curr Aging Sci 2014; 7: 101-109 [PMID: 25101650 DOI: 10.2174/1874609807666140327175404]

13. Pezzoli G, Cereda E. Exposure to pesticides or solvents and risk of Parkinson disease. Neurology 2013; 80: 2035-2041 [PMID: 23713084 DOI: 10.1212/01.wnl.0000131829.43659.5b]

14. Vlaar T, Kab S, Schwaab Y, Frey N, Elbaz A, Moisan F. Association of Parkinson's disease with industry and parkinsonism in three elderly populations of central Spain. Neurology 2013; 80: 2035-2041 [PMID: 23713084 DOI: 10.1212/01.wnl.0000131829.43659.5b]

15. Goldman SM. Environmental toxins and Parkinson's disease. Annu Rev Pharmacol Toxicol 2014; 54: 141-164 [PMID: 24005700 DOI: 10.1146/annurev-pharmtox-011613-135937]

16. Lin MK, Farooq MJ. Genetics and genomics of Parkinson's disease. Genome Med 2014; 6: 48 [PMID: 25861481 DOI: 10.1186/gm566]

17. Abieliovich A, Gitler AD. Defects in trafficking bridge Parkinson's disease pathology and genetics. Nature 2013; 536: 207-216 [PMID: 27830778 DOI: 10.1038/nature20414]

18. Klein C, Westerberger A. Genetics of Parkinson's disease. Cold Spring Harb Perspect Med 2012; 2: a008888 [PMID: 22313721 DOI: 10.1101/cshperspect.a008888]

19. Wood-Kaczmar A, Gandhi S, Wood NW. Understanding the molecular causes of Parkinson's disease. Trends Mol Med 2006; 12: 521-528 [PMID: 17027339 DOI: 10.1016/j.molmed.2006.09.007]

20. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211 [PMID: 12498954 DOI: 10.1016/S0197-4580(02)00905-9]

21. Perez-Roca L, Adame-Castillo C, Campdelacreu J, Ispiroi L, Vilas D, René A, Alvarez R, Gascon-Bayarri J, Serrano-Munoz MA, Ariza A, Beyer K. Glucocerebrosidase mRNA is Diminished in Brain of Lewy Body Diseases and Changes with Disease Progression in Blood. Aging Dis 2018; 9: 208-219 [PMID: 28998641 DOI: 10.14336/AD.2017.09.005]

22. Schissling C, Kiefer N, Seidel K, Krüger R. Review: Familial Parkinson's disease—genetics, clinical phenotype and neuropathology in relation to the common sporadic form of the disease. Neurobiol Appl Neurobiol 2008; 34: 255-271 [PMID: 18447897 DOI: 10.1111/j.1365-2990.2008.00952.x]

23. Carr J, de la Fuente-Fernández R, Schulzer M, Mak E, Calne SM, Calne DB. Familial and sporadic Parkinson's disease usually display the same clinical features. Parkinsonism Relat Disord 2003; 9: 201-204 [PMID: 12618054 DOI: 10.1016/S1353-8020(02)00048-2]
Kang JF, Tang BS, Guo JF. The Progress of Induced Pluripotent Stem Cells as Models of Parkinson’s Disease. Nat Rev Neurosci 2017; 18: 573-584 [PMID: 28878372 DOI: 10.1038/nrn.2017.107]

Potashkin JA, Blume SR, Runkle NK. Limitations of animal models of Parkinson’s disease. Parkinsons Dis 2010; 2011: 658083 [PMID: 21209719 DOI: 10.4061/2011/658083]

Su R, Sun M, Wang W, Zhang J, Lenz Z, Chen Q, Yian Z, Zhong Y, Wang X. A Novel Immunosuppressor, (S)-Hydroxytriptolide, Alleviates Movement Disorder and Neuroinflammation in a 6-OHDA Hemiparkinsonian Rat Model. Aging Dis 2017; 8: 31-43 [PMID: 28203480 DOI: 10.13463/2016.0929]

Hippkiss AR. On the relationship between Energy Metabolism, Proteostasis, Aging and Parkinson's Disease: Possible Causative Role of Methylglyoxal and Alleviative Potential of Carnosine. Aging Dis 2017; 8: 334-345 [PMID: 28580188 DOI: 10.13463/2016.1030]

Liu D, Li J, Li H, Fu Y, Wang W. Imaging and Quantitative Analysis of the Interstitial Space in the Caudate Nucleus in a Rotenone-Induced Rat Model of Parkinson's Disease Using Tracer-based MRI. Aging Dis 2017; 8: 1-6 [PMID: 28203477 DOI: 10.13463/2016.0625]

Chiba K, Trevor A, Castagnoli N. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 1984, 120: 574-578 [PMID: 6428396 DOI: 10.1006/bies.1996.0829]

Betalbert R, Sherer TB, Greenamrye JT. Animal models of Parkinson's disease. Bioessays 2002; 24: 308-318 [PMID: 11948617 DOI: 10.1002/bies.10067]

Schmidt WJ, Alam M. Controversies on new animal models of Parkinson's disease pro and con: the retorone model of Parkinson's disease (PD). J Neural Transm Suppl 2006; 273-276 [PMID: 17017541 DOI: 10.1007/3-211-45250-6_42]

Hipkiss ER, Sturley SL, Rouhi J, et al. The use of brain organoids to investigate neural development and disease. Neurosci Biobehav Rev 2018; 97: 334-345 [PMID: 30090649 DOI: 10.1016/j.neubiorev.2018.08.019]

Potashkin JA, Blume SR, Runkle NK. Limitations of animal models of Parkinson’s disease. Parkinsons Dis 2010; 2011: 658083 [PMID: 21209719 DOI: 10.4061/2011/658083]

Su R, Sun M, Wang W, Zhang J, Lenz Z, Chen Q, Yian Z, Zhong Y, Wang X. A Novel Immunosuppressor, (S)-Hydroxytriptolide, Alleviates Movement Disorder and Neuroinflammation in a 6-OHDA Hemiparkinsonian Rat Model. Aging Dis 2017; 8: 31-43 [PMID: 28203480 DOI: 10.13463/2016.0929]

Hippkiss AR. On the relationship between Energy Metabolism, Proteostasis, Aging and Parkinson’s Disease: Possible Causative Role of Methylglyoxal and Alleviative Potential of Carnosine. Aging Dis 2017; 8: 334-345 [PMID: 28580188 DOI: 10.13463/2016.1030]

Liu D, Li J, Li H, Fu Y, Wang W. Imaging and Quantitative Analysis of the Interstitial Space in the Caudate Nucleus in a Rotenone-Induced Rat Model of Parkinson’s Disease Using Tracer-based MRI. Aging Dis 2017; 8: 1-6 [PMID: 28203477 DOI: 10.13463/2016.0625]

Chiba K, Trevor A, Castagnoli N. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 1984, 120: 574-578 [PMID: 6428396 DOI: 10.1006/bies.1996.0829]

Betalbert R, Sherer TB, Greenamrye JT. Animal models of Parkinson’s disease. Bioessays 2002; 24: 308-318 [PMID: 11948617 DOI: 10.1002/bies.10067]

Schmidt WJ, Alam M. Controversies on new animal models of Parkinson's disease pro and con: the retorone model of Parkinson's disease (PD). J Neural Transm Suppl 2006; 273-276 [PMID: 17017541 DOI: 10.1007/3-211-45250-6_42]

Hipkiss ER, Sturley SL, Rouhi J, et al. The use of brain organoids to investigate neural development and disease. Neurosci Biobehav Rev 2018; 97: 334-345 [PMID: 30090649 DOI: 10.1016/j.neubiorev.2018.08.019]
controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells. Proc Natl Acad Sci U S A 2017; 114: E3679-E3688 [PMID: 28416701 DOI: 10.1073/pnas.1617259114].

Chung CV, Khurana V, Ashlock PK, Tardiff DF, Mazulli JR, Soldner F, Baru V, Lou Y, Freyson Y, Cho S, Mungenast AE, Muñafí J, Mitalipova M, Pluth MD, Jai NT, Schulz B, Lippl SR, Tsai LH, Kraine D, Buchwald SL, Jaenisch R, Lindquist S. Identification and rescue of α-synuclein toxicity in Parkinson patient-derived neurons. Science 2013; 342: 983-987 [PMID: 24158904 DOI: 10.1126/science.1245296].

Fliert A, Oliveira LM, Falomir-Lockhart LJ, Måk SK, Hesley J, Soldner F, Arndt-Jovin DJ, Jaenisch R, Langston JW, Jovin TM. Schizophrenia risk and α-synuclein B higher vulnerability and stress sensitivity of neuronal precursor cells carrying an alpha-synuclein gene triplication. PLoS One 2014; 9: e12413 [PMID: 25390032 DOI: 10.1371/journal.pone.012413].

Bouchouche A, Tahir H, Ben El Haj R, El Bayad K, Razine R, Tzourout S, Skalli A, Bouslam N, Elouardi L, Benomar A, Yahyaoui M, Regragui W. LRRK2 G2019S Mutation: Prevalence and Clinical Features in Moroccans with Parkinson's Disease. Parkinsonisms Dis 2017; 2014: 28461380 [PMID: 28416701 DOI: 10.1155/2017/241286].

Young JE, Boulanger-Weill J, Williams DA, Woodruff G, Buen F, Revilla AC, Herrera C, Israel MA, Yuan SH, Edland SD, Goldstein LS. Elucidating molecular phenotypes caused by the SORL1 Alzheimer's disease genetic risk factor using human induced pluripotent stem cells. Cell Stem Cell 2011; 8: 267-280 [PMID: 22110587 DOI: 10.1016/j.stem.2011.02.004].

Fernández-Santiago R, Carballo-Carbajal I, Castellano G, Torrent R, Richaud Y, Sánchez-Danés A, Coelho E, Tíscar I, Saiz Mdr, Fernandez L, Miño MD, Peña MD, Valcarce MC, Andrabi S, Guardia-Laguarta C, Kim JH, Zhang H, Muffat J, Mitalipova M, Pluth MD, Jai NT, Schulz B, Lippl SR, Tsai LH, Carrillo-Reid L, Mornacs R, G2019S Mutation: Prevalence and Clinical Features in Moroccans with Parkinson's Disease. Science 2011; 332: 1529-1546 [PMID: 23075850 DOI: 10.1126/science.115557].

Bartels T, Selkoe D. Parkinson-causing α-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation. Nat Commun 2015; 6: 7314 [PMID: 26076669 DOI: 10.1038/ncomms8314].

Byers B, Cord B, Nguyen HN, Rühe J, Leroi J, Nutter A, Shan B, Molokanova E, Zhang Y, Han X, Nakamura T, Masliah E, Yates JR, Nakashima N, Andreyev AY, Okamoto S, Jaenisch R, Ambasudhan R, Lipton SA. Isogenic human iPSC Parkinson's model shows nitrosative stress-induced dysfunction in a transcriptional degradation pathway. Proc Natl Acad Sci U S A 2013; 110: 11331-11336 [PMID: 24290359 DOI: 10.1073/pnas.1311609110].

Dettmer U, Newman AJ, Soldner F, Luth ES, von Saucken VE, Jaenisch R, Langston JW, Mungo J. Generation of isogenic pluripotent stem cells differing exclusively at two early embryonic transcription factors. Proc Natl Acad Sci U S A 2015; 112: 3081-3086 [PMID: 25390032 DOI: 10.1073/pnas.1415425112].

Fernández-Santiago R, Carballo-Carbajal I, Castellano G, Torrent R, Richaud Y, Sánchez-Danés A, Coelho E, Tíscar I, Saiz Mdr, Fernandez L, Miño MD, Peña MD, Valcarce MC, Andrabi S, Guardia-Laguarta C, Kim JH, Zhang H, Muffat J, Mitalipova M, Pluth MD, Jai NT, Schulz B, Lippl SR, Tsai LH, Carrillo-Reid L, Mornacs R, G2019S Mutation: Prevalence and Clinical Features in Moroccans with Parkinson's Disease. Science 2011; 332: 1529-1546 [PMID: 23075850 DOI: 10.1126/science.115557].

Bartels T, Selkoe D. Parkinson-causing α-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation. Nat Commun 2015; 6: 7314 [PMID: 26076669 DOI: 10.1038/ncomms8314].

Byers B, Cord B, Nguyen HN, Rühe J, Leroi J, Nutter A, Shan B, Molokanova E, Zhang Y, Han X, Nakamura T, Masliah E, Yates JR, Nakashima N, Andreyev AY, Okamoto S, Jaenisch R, Ambasudhan R, Lipton SA. Isogenic human iPSC Parkinson's model shows nitrosative stress-induced dysfunction in a transcriptional degradation pathway. Proc Natl Acad Sci U S A 2013; 110: 11331-11336 [PMID: 24290359 DOI: 10.1073/pnas.1311609110].

Dettmer U, Newman AJ, Soldner F, Luth ES, von Saucken VE, Jaenisch R, Langston JW, Mungo J. Generation of isogenic pluripotent stem cells differing exclusively at two early embryonic transcription factors. Proc Natl Acad Sci U S A 2015; 112: 3081-3086 [PMID: 25390032 DOI: 10.1073/pnas.1415425112].

Fernández-Santiago R, Carballo-Carbajal I, Castellano G, Torrent R, Richaud Y, Sánchez-Danés A, Vilarasa-Blasi R, Sánchez-Pla A, Mosquera JL, Soriano J, López-Barneo J, Canals JM, Albera J, Rayba À, Vila M, Consiglio A, Martin-Saburo JI, Esquerre M, Tolosa E. Aberrant epigenome in iPSC-derived dopaminergic neurons from Parkinson's disease patient. AMBO Mol Med 2015; 7: 1529-1546 [PMID: 26565212 DOI: 10.10224/cnmn.201550439].

Pickrell AM, Youle RJ. The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease. Trends Neurosci 2014; 37: 315-324 [PMID: 24735649 DOI: 10.1016/j.tins.2013.04.004].

Jiang Q, Feng J. Parkin increases dopamine uptake by enhancing the cell surface expression of dopamine transporter. J Biol Chem 2004; 279: 54380-54386 [PMID: 15490201 DOI: 10.1074/jbc.M409282200].

Imazumi Y, Okada Y, Akamatsu W, Kojima M, Kuzumaki N, Hayakawa H, Niihara T, Kobayashi T, Ohyama M, Sato S, Takanashi M, Funayama M, Hiyama A, Soga T, Hishiki T, Suenatsu M, Yagi T, Ito D, Kosakai A, Hayashi K, Shoji M, Nakashita A, Suzuki N, Mizuno Y, Mizushima N, Amagai K, Uchiyama Y, Mochizuki H, Hattori N, Okano H. Mitochondrial dysfunction associated with increased oxidative stress and α-synuclein accumulation in PARK2 iPS-derived neurons and postmortem brain tissue. Mol Brain 2012; 5: 35 [PMID: 23039195 DOI: 10.1186/1756-6606-5-35].
Psathaki OE, Klingauf J, Kuhlmann T, Klewin M, Müller H, Gasser T, Schöler HR, Sterneckert J. Genetic
2016; Zhang F. Applications of CRISPR-Cas systems in neuroscience. Dis Model Mech 2016; 896-904 [PMID: 23751357 DOI: 10.1242/dmm.012054]
FEBS J 2016; 283-284 [PMID: 25323110 DOI: 10.1002/sea.1854]
Seibler P, Graziotto, Joerg H, Simonovic F, Klein C, Kraeic D. Mitochondrial PARKin recruitments are impaired in neurons derived from mutant PINK1 induced pluripotent stem cells. J Neurosci 2011; 31: 5970-5976 [PMID: 21508222 DOI: 10.1523/JNEUROSCI.4441-10.2011]
Shaltouki A, Sivapatham R, Fei Y, Gerencser AA, Mocmilslov O, Rao MS, Zeng X. Mitochondrial alterations by PANKIN in dopaminergic neurons using PARK2 patient-specific and PARK2 knockout isogenic iPSC lines. Stem Cell Reports 2015; 4: 847-859 [PMID: 25940645 DOI: 10.1016/j.stemcr.2015.02.019]
Ortega RA, Torres PA, Swan M, Nichols W, Bosching S, Raymond D, Barrett MJ, Johannes BA, Severt L, Shanker V, Hunt AL, Bressman S, Pastores GM, Saunders-Pullman R. Glucocerebrosidase enzyme activity in GBA mutation Parkinson’s disease. J Clin Neuroscience 2016; 28: 185-186 [PMID: 26857920 DOI: 10.1016/j.jocn.2015.12.001]
Afflak E, Borger DK, Moaven N, Stubblefield BK, Rogers SA, Patrauk S, Schoenexn FJ, Westbroek W, Zheng W, Sullivan P, Fujwara H, Sidhu R, Khalaq ZM, Lopez GJ, Goldstein DS, DRY DS, Maragan J, Sridhanks E. A New Glucocerebrosidase Chaperone Reduces α-Synuclein and Glycosid Lipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism. J Neurosci 2016; 36: 7441-7452 [PMID: 27413154 DOI: 10.1523/JNEUROSCI.0636-16.2016]
Woodard CM, Campos BA, Kuo SH, Niremberg MJ, Nestor MW, Zimmer M, Mosharov EV, Sulzer D, Zhou H, Paull D, Clark L, Schadt EE, Sardi SP, Rubin L, Eggan K, Brock M, Lipnick S, Rao M, Chang S, Li A, Noggle SA. iPSC-derived dopamine neurons reveal differences between monozygotic twins discordant for Parkinson’s disease. Cell Rep 2014; 9: 1173-1182 [PMID: 25456120 DOI: 10.1016/j.celrep.2014.10.023]
Schönfors DC, Aureli M, McAllister FE, Hindley CJ, Mayer F, Schmid B, Sardi SP, Valsecchi M, Hoffmann S, Schwarz LK, Hedinrich U, Berg D, Shibli-Auddin LS, Hu J, Prusak S, Gygi SP, Sonnilo M, Gasser T, Deledel M. iPSC-derived neurons from GBA1-associated Parkinson’s disease patients show autophagic defects and impaired calcium homeostasis. Nat Commun 2014; 5: 4028 [PMID: 24995578 DOI: 10.1038/ncomms5028]
Soldner F, Hackemeyer D, Beard C, Gao Q, Bell GW, Cook EG, Hargus G, Blak A, Cooper O, Mitalipova M, Isacion O, Jaenisch R. Parkinson’s disease patient-induced pluripotent stem cells free of viral reprogramming factors. Cell 2009, 136; 964-977 [PMID: 19269371 DOI: 10.1016/j.cell.2009.02.013]
Sánchez-Danés A, Richaud-Patin Y, Carballo-Carbalaj I, Jiménez-Delgado S, Caig C, Mora S, Di Guglielmo C, Ezquerra M, Patera B, Pirital A, Canals JM, Memo M, Alberich J, López-Barrao J, Vila M, Cuerow AM, Tolosa E, Consiglio A, Raya A. Disease-specific phenotypes in dopamine neurons from human iPSC-based models of genetic and sporadic Parkinson’s disease. EMBO Mol Med 2012; 4: 380-395 [PMID: 22407749 DOI: 10.1002/emmm.201200215]
Schulze M, Sommer A, Plütz S, Farrell M, Winner B, Grosch J, Winkler J, Riemenschneider MJ. Sporadic Parkinson’s disease derived neuronal cells show disease-specific mRNA and small RNA signatures with abundant deregulation of piRNAs. Acta Neuropathol Commun 2018; 6: 58 [PMID: 29896768 DOI: 10.1186/s40478-017-0561-x]
Seto AG, Kingman RE, Lau NC. The coming of age for Piwi proteins. Mol Cell 2007; 26: 603-609 [PMID: 17560367 DOI: 10.1016/j.molcel.2007.05.021]
Sioni MC, Sato K, Pezic D, Aravin AA. Piwi-interacting small RNAs: the vanguard of genome defence. Nat Rev Mol Cell Biol 2011; 12: 246-258 [PMID: 21427766 DOI: 10.1038/nrm3080]
Booth HDE, Hirst WD, Wade-Martins R. The Role of Astrocyte Dysfunction in Parkinson’s Disease Pathogenesis. Trends Neurosci 2017; 38: 358-370 [PMID: 28527591 DOI: 10.1016/j.tins.2017.04.001]
Gunhanlar N, Shpak G, van der Kroeg M, Gouty-Colomer LA, Muinshi S, Pezic D, Aravin AA. PIWI-interacting small RNAs: the vanguard of genome defence. Nat Rev Mol Cell Biol 2011; 26: 603-609 [PMID: 19269371 DOI: 10.1016/j.cell.2009.02.013]
Santos R, Vadodaria KC, Jaeger BN, Mei A, LeFlochinos-Fogelquist S, Mendes APD, Eriksson G, Shokhirev M, Randolph-Moore L, Fredlender C, Dave S, Oefner R, Fitzpatrick C, Pena M, Barron JJ, Ku M, Denil AM, Kerman BE, Charnay P, Kelsoe JR, Marchetto MC, Gage FH. Differentiation of Dopaminergic Neurons Derived from iPSC. Stem Cell Reports 2018; 10: 366-374 [PMID: 29596183 DOI: 10.1016/j.stemcr.2017.12.011]
Lin J, Musumur K. Genome engineering tools for building cellular models of disease. FERS J 2016; 283: 3222-3231 [PMID: 27218233 DOI: 10.1111/febs.13763]
Musunuru K. Genome editing of human pluripotent stem cells to generate human cellular disease models. Dis Model Mech 2013; 6: 896-904 [PMID: 23751357 DOI: 10.1242/dmm.01204]
Heidenreich M, Zhang F. Applications of CRISPR-Cas systems in neuroscience. Nat Rev Neurosci 2016; 17: 36-44 [PMID: 26635263 DOI: 10.1038/nrn.2015.2]
Reinhardt P, Schmid B, Burbulla LF, Schönfors DC, Wagner L, Glatz A, Hoin S, Hargus G, Heck SA, Dihagla A, Wu G, Müller S, Brockmann K, Kluba T, Maisel M, Krüger R, Berg D, Tatsuya T, Thiels C, Pathaki OE, Klingauf J, Kuhlmann T, Klewin M, Müller H, Gasser T, Schöler HR, Sterneckert J. Genetic
correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. Cell Stem Cell 2013; 12: 354-367 [PMID: 23472874 DOI: 10.1016/j.stem.2013.01.008]

95 Sanders LH, Lagnadie J, Cooper O, Mak SK, Vu BJ, Huang YA, Paschen DE, Vangipuram M, Sundararajan R, Urunov FD, Langston JW, Gregory PD, Zhang HS, Greenamyre JT, Isacson O, Schüle B. LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: reversal by gene correction. Neurobiol Dis 2014; 62: 381-386 [PMID: 24148834 DOI: 10.1016/j.nbd.2013.10.013]

96 Bozi M, Papadimitriou D, Antonellou R, Moraitou M, Manaiti M, Vassiliatis DK, Papageorgiou SG, Leonarods A, Tagaris G, Malamis G, Theofilopoulos D, Kamakari S, Stamboulis E, Hadji Georgiou GM, Athanasiadou A, Michelakakis H, Papadimitriou A, Gasser T, Stefanis L. Genetic assessment of familial and early-onset Parkinson's disease in a Greek population. Eur J Neurool 2014; 21: 963-968 [PMID: 24313877 DOI: 10.1111/ejn.12315]

97 Kim HJ, Jeon BS, Yoon MY, Park SS, Lee KW. Increased expression of α-synuclein by SNCA duplication is associated with resistance to toxic stimuli. J Mol Neurosci 2012; 47: 249-255 [PMID: 22392151 DOI: 10.1007/s12031-012-9372-6]

98 Arias-Fuenzalida J, Zarazo J, Qing X, Walter J, Gomez-Giro G, Nickels SL, Zahares H, Schöler HR, Schwamborn JC. FACS-Assisted CRISPR-Cas9 Genome Editing Facilitates Parkinson's Disease Modeling. Stem Cell Reports 2017; 9: 1423-1431 [PMID: 28988985 DOI: 10.1016/j.stemcr.2017.08.026]

99 Chinta SJ, Andersen JK. Dopaminergic neurons. Int J Biochem Cell Biol 2005; 37: 942-946 [PMID: 15743669 DOI: 10.1016/j.biocel.2004.09.009]

100 Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelaín M, Studer L. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signalling. Nat Biotechnol 2009; 27: 275-280 [PMID: 19252484 DOI: 10.1038/nbt.1529]

101 Kriks S, Shim JW, Pao J, Ganat YM, Wakeman DR, Xie Z, Czarrillo-Reid L, Auyeung G, Antonacci C, Buch A, Yang L, Beal MF, Surmeier DJ, Kordower JH, Tabar V, Studer L. Dopamine neurons derived from human ES cells efficiently engraf in animal models of Parkinson's disease. Nature 2011; 480: 547-551 [PMID: 22056989 DOI: 10.1038/nature10648]

102 Swistowski A, Peng J, Liu Q, Mali P, Rao MS, Cheng L, Zeng X. Efficient generation of functional dopaminergic neurons from human induced pluripotent stem cells under defined conditions. Stem Cells 2010; 28: 1893-1904 [PMID: 20715183 DOI: 10.1002/stem.499]

103 Hynes M, Poulsen K, Tesser-Lavigne M, Rosenhthal A. Control of neuronal diversity by the floor plate: contact-mediated induction of midbrain dopaminergic neurons. Cell 1995; 80: 95-101 [PMID: 7813022 DOI: 10.1002/0092-8674(95)90454-9]

104 Giordano S, Darley-Usmar V, Zhang J. Autophagy as an essential cellular antioxidant pathway in neurodegenerative disease. Redox Biol 2013; 2: 82-90 [PMID: 24494187 DOI: 10.1016/j.redox.2013.12.013]

105 Cooper O, Hargus G, Deleidi M, Blak A, Osborn T, Marlow E, Lee K, Levy A, Perez-Torres E, Yow A, Isacson O. Differentiation of human ES and Parkinson's disease iPS cells into ventral midbrain dopaminergic neurons requires a high activity form of SHH, FGFR8 and specific regionalization by retinoic acid. Mol Cell Neurosci 2010; 45: 258-266 [PMID: 20860326 DOI: 10.1016/j.mcn.2010.06.017]

106 Yao EJ, Hwang YC, Feng CM, Kim HH, Kim DI, Park YW, Park SC. Senescence-like changes induced by hydroxyurea in human diploid fibroblasts. Exp Gerontol 2000; 35: 553-571 [PMID: 10978678 DOI: 10.1016/S0531-5565(00)00108-X]

107 Dong CM, Wang XL, Wang GM, Zhang WJ, Zhu L, Gao S, Yang DJ, Qin Y, Liang YL, Deng HT, Ning K, Liang AB, Guo ZL, Xu J. A stress-induced cellular aging model with postnatal neural stem cell conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol 2009; 27: 275-280 [PMID: 19252484 DOI: 10.1038/nbt.1529]

108 Tan Y, Ke M, Huang Z, Chong C, Cen X, Lu JH, Yao X, Qin D, Su H. Hydroxyurea facilitates differentiation and Its Applications in Neurotrauma. Front Mol Neurosci 2017; 10.1038/s41199-017-0036-x

109 Tong G, Izquierdo P, Raahed RA. Human Induced Pluripotent Stem Cells and the Modelling of Alzheimer’s Disease: The Human Brain Outside the Dish. Open Neurol J 2017; 11: 27-38 [PMID: 29151980 DOI: 10.2174/1874205X1711100207]

110 Deng W. Induced pluripotent stem cells: paths to new medicines. A catalyst for disease modelling, drug discovery and regenerative therapy. EMBO Rep 2010; 11: 161-165 [PMID: 20168328 DOI: 10.1038/embor.2010.15]

111 Bahmad H, Hadadeh O, Channa F, Cheaito K, Darwish B, Makkawi AK, Abou-Kheir W. Modeling Human Neurological and Neurodegenerative Diseases: From Induced Pluripotent Stem Cells to Neuronal Differentiation and Its Applications in Neurotrauma. Front Mol Neurosci 2017; 10: 50 [PMID: 28293108 DOI: 10.3389/fninf.2017.00050]

112 Winkhofer KF, Haas C. Mitochondrial dysfunction in Parkinson's disease. Biochim Biophys Acta 2010; 1802: 29-44 [PMID: 19733240 DOI: 10.1016/j.bbadis.2009.08.013]

113 Perreito R, Cunha-Oliveira T, Rego AC. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson's disease-resemblance to the effect of amphetamine drugs of abuse. Free Radic Biol Med 2013; 62: 186-201 [PMID: 23743292 DOI: 10.1016/j.freeradbiomed.2013.05.042]

114 Jankovic J, Aguilar LG. Current approaches to the treatment of Parkinson's disease. Neurophychiatr Dis Treat 2008; 4: 743-757 [PMID: 19043519 DOI: 10.2147/ndt.s2006]

115 Bové J, Perier C. Neurotoxin-based models of Parkinson’s disease. Neuroscience 2012; 211: 51-76 [PMID: 22188613 DOI: 10.1016/j.neuroscience.2011.10.057]

116 Morizana A, Takahashi J. Cell Therapy for Parkinson's Disease. Neurol Med Chir (Tokyo) 2016; 56: 102-109 [PMID: 26922955 DOI: 10.2176/ncm.ra.2015-0303]

117 Takagi Y, Takahashi H, Morizana A, Hayashi T, Kishi Y, Fukuda H, Okamoto Y, Koyanagi M, Ideguchi M, Hayashi H, Imazato T, Kawasaki H, Suemori H, Ouchida S, Iida H, Itoh N, Nakatsuji N, Sasaki Y, Hashimoto N. Dopaminergic neurons generated from monkey embryonic stem cells functioned in the human Parkinson primate model. J Clin Invest 2005; 115: 102-109 [PMID: 15690489 DOI: 10.1172/JCI21137]

118 Hallett PJ, Deleidi M, Astradsson A, Smith GA, Cooper O, Osborn TM, Sundberg M, Moore MA, Perez-Torres E, Brownell AL, Schumacher JM, Spealman RD, Isacson O. Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson’s disease. Cell Stem Cell 2015; 16: 269-274 [PMID: 25732245 DOI: 10.1016/j.stem.2015.03.008]

119 Yasuhara T, Kameda M, Sasaki T, Tajiri N, Date I. Cell Therapy for Parkinson's Disease. Cell Transplant
2017; 26: 1551-1559 [PMID: 29113472 DOI: 10.1177/0963689717735411]

120 **Liras A.** Future research and therapeutic applications of human stem cells: general, regulatory, and bioethical aspects. *J Transl Med* 2010; 8: 131 [PMID: 21143967 DOI: 10.1186/1479-5876-8-131]

121 **Garitaonandia I, Gonzalez R, Sherman G, Semechkin A, Evans A, Kern R.** Novel Approach to Stem Cell Therapy in Parkinson's Disease. *Stem Cells Dev* 2018; 27: 951-957 [PMID: 29882481 DOI: 10.1089/scd.2018.0001]
